Today: 14 June 2026
Browse Category

NASDAQ:REPL 21 October 2025

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Replimune shares jumped 99% to $8.94 on Oct. 20, 2025, after the FDA accepted its resubmitted BLA for lead cancer therapy RP1 plus nivolumab, setting a PDUFA decision date for April 10, 2026. New trial data showed a 44% response rate in acral melanoma. The stock’s rebound follows a 73% plunge in July after an FDA rejection. Market cap stands near $698 million.
21 October 2025
·

Stock Market Today

  • Mega-IPOs Flood Market: Sign of US Stock Downturn or Bullish Cycle?
    June 13, 2026, 7:59 PM EDT. The surge in large initial public offerings (IPOs) like SpaceX's $75 billion debut and upcoming AI giants OpenAI and Anthropic has Wall Street split over the market outlook. Capital Economics flags historical patterns where heavy equity issuance preceded major market peaks and recessions, citing parallels to 1999, 2007, and 2021. Conversely, Deutsche Bank analysts argue that equity supply waves align with strong market returns, driven by robust earnings and heightened risk appetite. They note issuance typically follows strong demand rather than causing market declines. With Alphabet's recent $85 billion secondary offering and continued robust earnings, the stock market shows resilience amid increased equity issuance, leaving investors cautious but still optimistic about continued gains.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
Go toTop